FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, specifically to nephrology, and can be used to treat kidney disease. Pharmaceutical compositions of the invention include a ROBO2 inhibitor.
EFFECT: use of inventions enables to treat kidney disease, accompanied by a change in the structure of the podocyte legs, due to the normalisation of this structure under the influence of the ROBO2 inhibitor on the SLIT-ROBO2 signalling pathway and negative regulation of the polymerisation of the podocyte F-actin cytoskeleton.
24 cl, 4 tbl, 8 dwg
Title | Year | Author | Number |
---|---|---|---|
RECOMBINANT ROBO2 PROTEINS, COMPOSITIONS, METHODS AND THEIR USE | 2018 |
|
RU2791486C2 |
NEUROENDOCRINE FACTORS FOR TREATING DEGENERATIVE DISORDERS | 2008 |
|
RU2496790C2 |
COMPOSITION FOR PREVENTING OR TREATING RENAL DISEASES, CONTAINING DPP-IV INHIBITOR | 2014 |
|
RU2652343C2 |
VAP-1 INHIBITORS ADMINISTRATION FOR FIBROID DISEASES TREATMENT | 2010 |
|
RU2667963C1 |
ACTIVIN-ACTRII ANTAGONISTS AND USES THEREOF FOR TREATING BONE AND OTHER DISORDERS | 2013 |
|
RU2678117C2 |
CXCL13 ANTAGONISTS AND APPLICATION THEREOF FOR TREATING INFLAMMATORY DISEASES | 2007 |
|
RU2449808C2 |
POLYPEPTIDES AND POLYNUCLEOTIDES AND THEIR USE FOR TREATMENT OF IMMUNE DISORDERS AND CANCER | 2012 |
|
RU2623161C2 |
ALPORT SYNDROME TREATMENT OPTIONS | 2018 |
|
RU2791694C2 |
USE OF VAP-1 INHIBITORS FOR FIBROTIC SICKNESS TREATMENT | 2010 |
|
RU2580626C2 |
ANTIBODIES TO CD38 AND PHARMACEUTICAL COMPOSITIONS BASED THEREON FOR TREATMENT OF AUTOIMMUNE DISEASE MEDIATED BY AUTOANTIBODIES | 2020 |
|
RU2809565C2 |
Authors
Dates
2018-12-05—Published
2013-01-04—Filed